PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Scientific Reports0 citationsOpen Access

The antibacterial effectiveness of fourth-generation poly-amidoamine dendrimers-loaded with amoxicillin in combating methicillin-resistant Staphylococcus aureus

NANaifa AlenaziSASamiah A. AlhabardiRBReem Binsuwaidan

Key Points

  • The aim is to explore the effectiveness of fourth-generation PAMAM dendrimers loaded with amoxicillin against MRSA.
  • Investigated the physicochemical characteristics of PAMAM G4-amoxicillin formulation.
  • Conducted in vitro analyses including zetasizer and transmission electron microscopy.
  • Assessed antibacterial activity using minimum inhibitory concentration and growth assays.
  • Evaluated biofilm inhibition and hemolytic activity with specific assays.
  • PAMAM G4-amoxicillin showed a minimum inhibitory concentration of 0.25 mg/ml.
  • Significant antibacterial activity observed, outperforming blank G4 and amoxicillin alone.
  • Inhibition of 70% of biofilm formation against MRSA.
  • Complete prevention of hemolytic activity in MRSA was demonstrated.

Abstract

In the community and in healthcare, methicillin-resistant Staphylococcus aureus (MRSA) is a major concern. Numerous infections with significant rates of morbidity and mortality are caused by MRSA strains worldwide. The widespread synthesis of virulence components is what makes MRSA so successful. The increasing resistance of MRSA to conventional antibiotics necessitates urgent exploration of alternative treatment strategies. One promising approach involves the use of fourth-generation poly-amidoamine dendrimers (PAMAM) loaded with amoxicillin, a critical β-lactam antibiotic for treating Gram-positive infections, although its efficacy is hindered by MRSA resistance. This study investigates the application of PAMAM G4 with amoxicillin to address this resistance, thereby optimizing the use of amoxicillin and potentially reducing the time and costs associated with developing new therapeutic agents. The physicochemical characteristics of the formulation were assessed through various in vitro analyses, including zetasizer and transmission electron microscopy, revealing a particle size of 219 nm, a zeta potential of -19 mV, and drug enacpsulation efficiency of 90.31%. The G4-amoxicillin dendrimer exhibited significant antibacterial activity, with a minimum inhibitory concentration of 0.25 mg/ml, as evidenced by growth assays in comparison to blank G4 and amoxicillin alone. Furthermore, the formulated nanoparticles demonstrated a substantial inhibition zone in the Kirby-Bauer Disk Diffusion method and exhibited strong anti-virulence properties, inhibiting 70% of biofilm formation and completely preventing hemolytic activity in MRSA, as shown in hemolysis assays. The formulated nanoparticles showed an effective antibacterial and anti-virulence activity against MRSA. Overall, the study added an evidence for a potential strategy to treat S. aureus and MRSA infection using nanoparticles and a potential reuse of amoxicillin.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Alenazi et al. (2026) studied this question.

synapsesocial.com/papers/6996a77aecb39a600b3ed27chttps://doi.org/10.1038/s41598-026-39752-5
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Synergistic bactericidal activity of a novel dual β-lactam combination against methicillin-resistant Staphylococcus aureus2024 · 8 citations
  2. 2HAP-Based Nanocomposite and Vitamin C for Sustained Drug Delivery of Amoxicillin2024 · 8 citations
  3. 3Control of Methicillin-Resistant Staphylococcus aureus Strains Associated With a Hospital Outbreak Involving Contamination From Anesthesia Equipment Using UV-C2020 · 17 citations
  4. 4Biosynthesis Strategy of Gold Nanoparticles and Biofabrication of a Novel Amoxicillin Gold Nanodrug to Overcome the Resistance of Multidrug-Resistant Bacterial Pathogens MRSA and E. coli2023 · 15 citations
  5. 5Polymicrobial antibiofilm activity of the membranotropic peptide gH625 and its analogue2018 · 42 citations